title: [Trigeminal autonomic cephalgias: diagnostic and therapeutic implications].
abstract: Trigeminal autonomic cephalgias (TACs) are primary headache syndromes characterized by severe short-lasting headaches accompanied by ipsilateral facial autonomic symptoms. The group includes cluster headache (CH), paroxysmal hemicrania (PH), and short-lasting neuralgiform headache with conjunctival injection and tearing (SUNCT). By far, Cluster headache is the most frequent of these syndromes. Similar hypothalamic and trigeminovascular mechanisms have been discussed as pathophysiologic mechanisms for all TACs. The therapeutic strategies, however, differ considerably. Although unusual, structural lesions in TACs have been described, affecting the therapeutic management.
authors.affiliation: Neurologische Klinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar, München. nmirjam@gmx.net
authors.forename: Mirjam
authors.initials: M
authors.lastname: Rosenberg-Nordmann
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Tölle
authors.forename: Till
authors.initials: T
authors.lastname: Sprenger
mesh_terms: D000281:Administration, Intranasal; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D003027:Cluster Headache / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D003937:Diagnosis, Differential; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008279:Magnetic Resonance Imaging; D023303:Oxazolidinones / Q000008:administration & dosage / Q000627:therapeutic use; D051302:Paroxysmal Hemicrania / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D050798:SUNCT Syndrome / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D018170:Sumatriptan / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D051303:Trigeminal Autonomic Cephalalgias / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D014363:Tryptamines / Q000008:administration & dosage / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014665:Vasodilator Agents; C089750:zolmitriptan; D018170:Sumatriptan; D014700:Verapamil; D007213:Indomethacin